Brought to you by 
Series B for Presidio brings in $26mm; adds $27mm
10 Jul 2009
Executive Summary
Presidio Pharmaceuticals (therapeutics for viral infections) raised $26mm in a Series B financing round led by new backer Panorama Capital with additional participation from other first-time investors Baker Brothers Investments, Bay City Capital, Ventures West Capital, and Nexus Medical Partners, and returning shareholders Sagamore Bioventures, George Rathmann Fund, and Peninsula Overview Partners. A representative each from Panorama Capital, Baker Bros., Bay City Capital, and Ventures West Capital will join Presidio's board. The company will use part of the funds to move two HIV candidates into clinical trials. As a result of the financing, Presidio's licensing partner Medivir received Series B shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B for Presidio brings in $26mm; adds $27mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice